Immutep (ASX:IMM) has reported encouraging early progress in developing a first-in-class therapy that could reshape how autoimmune diseases are treated, following completion of a key stage in its first human clinical trial.

In a move that signals growing momentum for Australia’s role in advanced therapeutics, Viral Vector Manufacturing Facility has entered into a licensing agreement with global cell and gene therapy specialist OXB, opening the door to critical viral vector technologies and strengthening the nation’s position in a rapidly expanding field.

AdAlta (ASX:1AD) has moved to strengthen its strategic and market-facing capabilities with the appointment of experienced corporate executive Fadi Diab to its Board as a non-executive director.

Racura Oncology (ASX:RAC) has reached a key clinical milestone with the successful dosing of a patient in Hong Kong, marking both geographic expansion and the completion of the first cohort in its early-stage trial of RC220, a candidate designed to deliver both anticancer activity and cardioprotection.

Australia’s life sciences sector has welcomed a major national push to strengthen research, development and innovation, with industry leaders urging coordinated government action to secure the country’s economic and health future.

Researchers have confirmed that Kappa Myeloma Antigen and Lambda Myeloma Antigen appear on malignant plasma cells but not on healthy ones, opening the door to treatments that could attack cancer cells with far greater precision while sparing the normal immune system.

A coin-sized implantable sensor designed to monitor pressure inside the brain has been approved for use in Australia, offering clinicians a new way to manage hydrocephalus and potentially reducing the need for repeated scans and surgical interventions.

The Sydney-based medical device company announced that its non-renounceable entitlement offer had raised about $2 million and was fully subscribed, including the underwriting commitment from Bell Potter Securities.

Firebrick Pharma has appointed experienced pharmaceutical executive Nilesh Wadhwa to lead its global business development and licensing efforts as the company pushes to rapidly expand international approvals and sales of its Nasodine product range.

The Perth and San Francisco-based biotechnology company announced that discussions with the FDA confirmed key elements of the clinical trial required to support a future New Drug Application for the therapy.

Australian immuno-oncology company Imugene (ASX:IMU) has moved to accelerate development of its lead cancer therapy after reporting encouraging clinical results, while launching a capital raising to fund the next phase of trials.

Patrys (ASX:PAB) has taken significant steps toward advancing a potential new treatment for delirium into human clinical trials, including manufacturing and regulatory preparations for its experimental drug candidate RLS-2201.

Tetratherix (ASX:TTX) has taken a significant step forward in the development of its prostate cancer technology, advancing its Tutelix spacer toward an international pivotal trial following encouraging early clinical results and the successful completion of a Series A capital raise by its joint venture partner.

Mesoblast (ASX:MSB) has appointed physician scientist Dr Teresa Montagut to lead its clinical development and medical affairs efforts, strengthening the company’s leadership team as it expands its portfolio of cell therapies for inflammatory diseases.

Telix Pharmaceuticals (ASX:TLX) has reported positive early outcomes from the first part of its global Phase 3 ProstACT study, marking an important step in the development of a new targeted treatment for advanced prostate cancer.

The $1.5 billion project builds on more than $3 billion the global biopharmaceutical company has already invested in its United States operations since 2018 and is expected to create at least 300 new jobs alongside hundreds of construction roles.

Imugene (ASX:IMU) has reported encouraging early clinical results from its ongoing Phase 1b study of Azer Cel, an off-the-shelf CAR T cell therapy designed to treat several advanced blood cancers.

Nanosonics (ASX:NAN) has reached an important regulatory milestone after the United States Food and Drug Administration granted 510(k) clearance that broadens the range of endoscopes compatible with the company’s CORIS system.